跳至主要内容
临床试验/NCT04780893
NCT04780893撤回不适用

A Randomized, Double Blind Sham Controlled, Pilot Study to Evaluate the Efficacy of Vestibular Nerve Stimulation (VeNS) for Sleep Management in People With Post- Traumatic Stress Disorder (PTSD).

Neurovalens Ltd.0 个研究点开始时间: 2022年2月1日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
主要终点
Insomnia Severity Index (ISI) score

研究概览

简要总结

This double blind randomized controlled study will enroll 20 subjects and will be conducted remotely. The study will be randomized for an 8-week period with a 1:1 active to sham device allocation. Primary endpoint analysis will be performed at 4 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent
  • Diagnosed PTSD by a medical practitioner
  • Post-Traumatic Checklist (PCL-5) score of 31 or above
  • Insomnia Severity Index (ISI) score of 15 or above
  • Male or female, age ≥ 18 years and ≤ 80 years at the time of signing informed consent
  • Ability and willingness to complete all study visits and procedures, including completion of mental health questionnaires
  • Ability and willingness to adhere to 30 minutes usage of the device daily for the duration of the study
  • No change to PTSD, mental health or insomnia medication within the past 3 months (regimen should be stable)
  • Agreement not to change usage of prescription or over the counter PTSD, mental health or insomnia medications for the duration of the study
  • Agreement not to undergo any significant lifestyle changes that may affect sleep (e.g., excessive exercise, sleep interventions etc.) for the duration of the study
  • Agreement not to use sleep trackers (e.g., Fitbit) for the duration of the study
  • Agreement not to travel across different time zones for the duration of the study
  • Access to Wi-Fi (to enable the study app to upload usage data)
  • Access to computer, laptop, iPad or tablet (to conduct remote study visits and complete study questionnaires remotely)
  • Willing to download and use Zoom (to conduct remote study visits)

排除标准

  • History of skin breakdown, eczema, or other dermatological condition (e.g., psoriasis) affecting the skin behind the ears
  • Previous diagnosis of HIV infection or AIDS (HIV is known to cause vestibular neuropathy which would prevent VeNS from working)
  • Use of beta-blockers within 1 month of starting the study
  • A history of stroke or severe head injury as defined by a head injury that required a craniotomy or endotracheal intubation (in case this damaged the neurological pathways involved in vestibular stimulation)
  • Presence of permanently implanted battery powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator etc.)
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method
  • Diagnosis of epilepsy
  • Diagnosis of active migraines
  • Previous use of Modius device
  • Participation in other research studies sponsored by Neurovalens
  • Participation in any other sleep or PTSD studies
  • Not fluent in English language
  • Have a member of the same household who is currently participating in this study
  • Failure to agree to use of device daily during study participation
  • History of vestibular dysfunction or other inner ear disease
  • Any other medical condition, or medication use, that in the opinion of the PI is likely to make the subject refractory to VeNS.

结局指标

主要结局

Insomnia Severity Index (ISI) score

时间窗: 4 weeks

To evaluate the effect of the Modius Sleep device, relative to control group on participants with insomnia. ISI is a self-report rating scale assessing the severity of insomnia symptoms (range 0-28) with higher scores indicating a more severe insomnia.

次要结局

  • PCL-5 Score(4 weeks)
  • SF-36 Score(4 weeks)
  • Generalised Anxiety Disorder (GAD-7) Scores(4 weeks)
  • Prescription reduction(4 weeks)

研究者

发起方
Neurovalens Ltd.
申办方类型
Industry
责任方
Sponsor

相似试验